Zhejiang Hisoar Pharmaceutical Co., Ltd. announced that its wholly owned subsidiary Zhejiang Hisoar Chuannan Pharmaceutical Co., Ltd. has received the Chemical API Marketing Authorization Approval Notice for adenosine cyclophosphate issued by the National Medical Products Administration, with registration number Y20240000147. Adenosine cyclophosphate is a vasodilator used to treat angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock, and it also has therapeutic effects on acute leukemia. According to data from Menet, sales of adenosine cyclophosphate for injection in China's urban public hospitals reached 305.84 million yuan in 2025. The company stated that approval of this API will enrich its specialty API product pipeline, optimize its industrial layout, and enhance overall competitiveness, but domestic production and sales can only begin after passing GMP compliance inspection. It will not have a significant impact on performance in the short term, and the timing and specific sales situation remain uncertain.
Zhejiang Hisoar Pharmaceutical Co LtdReceived marketing approval for adenosine cyclophosphate API, enriching pipeline and competitiveness.
